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Abstract
Since the identification of tau as the main component of neurofibrillary tangles in Alzheimer's
disease and related tauopathies, and the discovery that mutations in the tau gene cause
frontotemporal dementia, much effort has been directed towards determining how the aggregation
of tau into fibrillar inclusions causes neuronal death. As evidence emerges that tau-mediated
neuronal death can occur even in the absence of tangle formation, a growing number of studies are
focusing on understanding how abnormalities in tau (e.g. aberrant phosphorylation, glycosylation
or truncation) confer toxicity. Though data obtained from experimental models of tauopathies
strongly support the involvement of pathologically modified tau and tau aggregates in
neurodegeneration, the exact neurotoxic species remain unclear, as do the mechanism(s) by which
they cause neuronal death. Nonetheless, it is believed that tau-mediated neurodegeneration is
likely to result from a combination of toxic gains of function as well as from the loss of normal tau
function. To truly appreciate the detrimental consequences of aberrant tau function, a better
understanding of all functions carried out by tau, including but not limited to the role of tau in
microtubule assembly and stabilization, is required. This review will summarize what is currently
known regarding the involvement of tau in the initiation and development of neurodegeneration in
tauopathies, and will also highlight some of the remaining questions in need of further investigation.
Introduction
The accumulation of proteinaceous aggregates is a patho-
logical hallmark of many neurological diseases character-
ized by neuronal dysfunction and eventual cell death. In
tauopathies, as the name aptly implies, these aggregates
take the form of neurofibrillary tangles (NFT) composed
of tau. This group of diseases includes Alzheimer's disease
(AD), frontal temporal dementia with Parkinsonism
linked to chromosome 17 (FTDP-17), progressive supra-
nuclear palsy, Pick's disease and corticobasal degenera-
tion. In contrast to AD, for which the deposition of NFT
occurs only in neurons, tau-positive inclusions are
observed in glial cells in a variety of tauopathies [1]. Each
tauopathy exhibits a characteristic regional pattern of NFT
formation and the degeneration of vulnerable neuronal
networks follows a stereotypical pattern. For example,
NFT are distributed primarily to the entorhinal region,
hippocampus and cortex in AD, to the brain stem, basal
ganglia and cerebellum in progressive supranuclear palsy
and to the frontal and temporal cortex in FTDP-17.
Despite their diverse phenotype and distinct clinical pres-
entations, common to all tauopathies is the progressive
accumulation of NFT composed of insoluble, hyperphos-
phorylated tau in a filamentous form, such as twisted or
straight filaments or paired helical filaments (PHF).
Tau was first isolated in 1975 as a protein that co-purifies
with tubulin and has the ability to promote microtubule
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assembly in vitro [2,3]. As one of the principal compo-
nents of the cytoskeletal system, microtubules are
involved in the maintenance of neuronal morphology
and the formation of axonal and dendritic processes. In
addition to structural support, microtubules play a vital
role in cellular trafficking. By providing tracts for motor
proteins, like kinesins and dynein, they enable the trans-
port of cargo to specific parts of the cell. The cargo trans-
ported to and from pre- and postsynaptic sites is critical
for synaptic function and includes mitochondria, compo-
nents of synaptic vesicles and plasma membranes, ion
channels, receptors and scaffolding proteins. Synapses are
highly vulnerable to impairments in transport; therefore
perturbations in this system could cause malfunctions in
neurotransmission and signal propagation and lead to
synaptic degeneration.
The polymerization, stability and organization of micro-
tubules are regulated by microtubule-associated proteins,
such as MAP1, MAP2 and tau. Tau predominantly local-
izes to neuronal axons where it modulates the stability
and assembly of microtubules. In so doing, tau generates
a partially stable, but still dynamic, state in microtubules
important for axonal growth and effective axonal trans-
port. Tau, in a distinct phosphorylated form, is also
present in the somatodendritic compartment of neurons,
as well as in astrocytes and perineuronal glial cells [4,5].
In addition to binding microtubules, some studies [6-11],
but not all [12], provide evidence that tau can interact,
either directly or indirectly, with actin and affect actin
polymerization as well as the interaction of actin fila-
ments with microtubules. Tau may also interact with the
plasma membrane [13-15] and with several proteins
involved in signal transduction [16-22].
The tau protein is encoded by the MAPT gene located in
chromosome 17 [23]. In the adult human brain, alterna-
tive mRNA splicing of exons 2, 3 and 10 yields six tau iso-
forms (Fig. 1). The isoforms differ by the absence or
presence of one or two acidic inserts at the N-terminal,
and whether they contain three or four repeats of a con-
served tubulin binding motif at the C-terminal [24]. The
repeat region, present within the microtubule binding
domain, binds to microtubules and promotes their
assembly. Tau isoforms with four repeats (4R-tau) bind
microtubules with a greater affinity than isoforms with
three repeats (3R-tau), and can even displace the previ-
ously bound 3R-tau [25]. Phosphorylation of certain resi-
dues within the repeat region impairs the interaction
between tau and microtubules, leading to the detachment
of tau [26]. The N-terminal half of tau, known as the pro-
jection domain because it protrudes from the surface of
microtubules, includes the acidic region and a proline-
rich region. The projection domain is proposed to deter-
mine the spacing between microtubules [27], and may
play a role in the interactions between tau and other
cytoskeleton proteins, like neurofilament proteins [28].
Additionally, this domain associates with the plasma
membrane [13,14] and the PPXXP or PXXP motifs in the
proline-rich region are important for the association of
tau with certain proteins containing Src homology 3
domains (SH3).
Though the gene encoding tau is not genetically linked to
AD, mutations in MAPT cause FTDP-17 [29,30], and mis-
sense mutations have also been found in progressive
supranuclear palsy [31], corticobasal degeneration
[32,33] and in conditions that closely resemble Pick's dis-
ease [34,35], thus providing evidence that disrupting tau
homeostasis suffices to cause neurodegeneration (Fig. 1).
Tau gene polymorphisms have also been described and
two different haplotypes, H1 and H2, have been identi-
fied [36]. The H1 haplotype is a risk factor for progressive
supranuclear palsy and corticobasal degeneration, per-
haps due to increased tau expression or the imbalanced
expression of alternative tau transcripts (for review, see
[37]).
Tau mutations are known to alter the relative proportion
of various tau isoforms [29], impair the ability of tau to
bind and promote the assembly of microtubules [38-40],
or enhance the aggregation of tau into filaments [41,42].
It is therefore expected that tau-mediated neurodegenera-
tion is caused by a combination of toxic gains of function
incurred by abnormalities in tau, as well as from the
harmful consequences that result from the loss of normal
tau functions. Unfortunately, the exact mechanisms by
which abnormalities in tau initiate, or contribute, to neu-
ronal demise are not entirely understood. This review will
summarize what is currently known regarding the role of
tau in the initiation and development of neurodegenera-
tion in AD and related tauopathies, and will also highlight
some of the remaining questions in need of further inves-
tigation.
Filaments and neurotoxicity
NFT are one of the most striking pathological features in
tauopathies; therefore, much attention has focused on
understanding how the deposition of NFT cause neurode-
generation, in essence using a top-down approach to
investigating the mechanism of disease. Though the tau
hypothesis of neurodegeneration is evolving, it has long
been postulated that the aggregation of tau into filaments
and NFT results in a toxic gain of function. In AD, the
number of NFT in the neocortex positively correlates with
the severity of cognitive decline [43], and several missense
mutations in tau that cause frontotemporal dementia
accelerate tau filament assembly in vitro [42,41,44]. Thus,
it is assumed that NFT are directly able to induce neuronal
damage. Yet, given that tau is normally a highly solubleMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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A schematic representation of the human tau gene, mRNA and protein isoforms Figure 1
A schematic representation of the human tau gene, mRNA and protein isoforms. The human tau gene is located 
on chromosome 17q21 and contains 16 exons (panel B). White boxes represent constitutive exons and the gray or colored 
boxes represent alternatively spliced exons. Identified mutations in exons 1–13, and intron 10, of the tau gene are shown using 
the numbering of the 441-amino acid isoform of tau (panel A). Exon -1 is part of the promoter and is transcribed but not trans-
lated, as is the case for exon 14 (panel C). Exons 4A, 6 and 8 are not transcribed in human. Exons 2, 3 and 10 are alternatively 
spliced, as demonstrated by the different lines linking these exons (panel C), generating a total of 6 different mRNAs which are 
translated into six different tau isoforms (panel D). These isoforms differ by the absence or presence of one or two N-terminal 
inserts encoded by exon 2 (orange box) and 3 (yellow box), as well as the presence of either three or four repeat regions 
coded by exons 9, 10, 11 and 12 (black boxes) in the C-terminus. The second repeat, encoded by exon 10, is highlighted in 
green. Panel E indicates sites in the acidic, proline-rich, repeat and C-terminal regions of tau reported to be phosphorylated in 
vivo or in vitro.
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protein that does not readily aggregate into filaments, this
matter has been difficult to assess in experimental models
because of the resistance of tau to aggregate within an
ideal time-frame for culture studies or within an animal's
relatively short lifespan. Further complicating matters is
evidence that mouse tau appears to prevent tau aggrega-
tion in transgenic mice overexpressing wild-type human
tau (htau) [45]. By crossing tau knockout (tau-/-) mice
with transgenic 8c mice that express all six isoforms of
htau, Andorfer et al., (2003) generated mice that exclu-
sively express htau (called htau mice) [45]. These htau
mice develop AD-like pathology, with hyperphosphor-
ylated tau accumulating as aggregated PHF. Conversely,
even though 8c mice express high levels of both htau and
mouse tau, they do not develop tau pathology. Normal
adult mouse brains contain only 4R-tau isoforms, so the
main difference between 8c and htau mice is the presence
of mouse 4R-tau. It is thus likely that mouse 4R-tau pro-
tects transgenic mice expressing non-mutant htau from
developing neurofibrillary pathology. Nonetheless, trans-
genic mice that overexpress high levels of htau isoforms
containing aggregation-promoting mutations (e.g. P301L
tau) can develop tau pathology even in the presence of
endogenous mouse tau [46-48]. To accelerate tau aggrega-
tion in vitro, polyanionic cofactors or small molecule lig-
ands are often used to facilitate tau fibrilization. For
example, in a cell culture model overexpressing full-
length tau, Congo red treatment stimulates the formation
of filamentous tau aggregates and decreases cell viability
[49]. Since tau overexpression is not toxic in the absence
of the aggregation-inducer, these results suggest that tau
aggregation causes cell death or, at least, accelerates its
onset.
Because high concentrations of tau are required to pro-
mote tau fibrilization in experimental models, it is
believed that the enhanced ability of tau to form filamen-
tous inclusions in the cytoplasm of neurons and glia in
human tauopathies may be due to pathological condi-
tions that increase the pool of tau available for aggrega-
tion. Elevated levels of free tau, not bound to
microtubules, would presumably enhance the assembly
of tau into oligomers and could increase its likelihood to
become misfolded, as well as undergo modifications or
conformational changes that promote the formation of
insoluble filamentous inclusions. Yet, while tau protein
levels are increased in the AD brain [50], it is unlikely that
the amount of tau in various tauopathies is as high as in
cell culture and animal models that artificially force tau
overexpression. It remains possible, however, that local
tau concentrations may be increased in restricted areas of
the cell during disease and this initiates the polymeriza-
tion of tau leading to NFT formation.
There are a number of ways by which NFT may damage
neurons and glial cells. For example, by acting as physical
barriers in the cytoplasm, NFT would compromise normal
cellular functions. In transgenic mice expressing mutant
(P301L) htau, the accumulation of tau filaments in the
cell body of neurons not only displaces many cytoplasmic
organelles from their usual location but also decreases the
number of normal organelles [51]. Of interest, PHF-tau,
either isolated from AD brains or generated in vitro, inhib-
its proteasome activity [52], and could therefore unfavo-
rably perturb cellular homeostasis. In a similar fashion,
the proteasome activity in HEK293 cells stably expressing
tau is decreased following tau hyperphosphorylation and
aggregation [53]. These findings are consistent with the
notion that protein aggregates are not inert end-products
but actively influence cell metabolism, like proteasomal
activity [54]. NFT may also cause neuronal toxicity by
reducing normal tau function. Since tau is redistributed to
filaments in AD [55], and since filamentous tau does not
promote microtubule assembly in vitro [56], the seques-
tration of tau to NFT may disrupt tau-mediated regulation
of microtubule dynamics. However, the reduction in
microtubule number and length observed in AD does not
correlate with the presence of PHF [57,58]. Furthermore,
whether the loss of functional tau alone is sufficient to
cause microtubule destabilization is under some debate.
Tau deficiency does delay the maturation and extension of
neurites in embryonic neuronal cultures [59,60] but no
major cytoskeletal abnormalities are observed in adult
tau-/- mice [61]. The lack of an obvious phenotype in tau-
/- mice is most probably due to a redundancy in function
among tau and other microtubule-associated proteins and
their apparent compensation for the loss of tau [62]. Nev-
ertheless, the overt breakdown of the microtubule system
may not be required to cause neuronal injury. For
instance, several mutations that cause tau dysfunction and
neuronal death in FTDP-17 alter the ratio of 4R-tau to 3R-
tau, and these isoforms differentially modulate microtu-
bule dynamics [63]. Thus, less obvious changes in the reg-
ulation of microtubules may have harmful consequences.
In any event, NFT need not alter microtubule integrity in
order to aberrantly affect one of the main functions of
microtubules, namely fast axonal transport. In a recent
study, LaPointe et al., (2008) demonstrated that filaments
formed by the longest isoform of htau impair antero-
grade, but not retrograde, transport in isolated squid axo-
plasm without producing changes in microtubule
morphology [64]. Filaments of htau appear to inhibit
anterograde transport by dissociating kinesin-1 from its
vesicular cargo and this effect is mediated by protein
phosphatase 1 (PP1) and glycogen synthase kinase-3
(GSK-3) [64]. Overall, NFT may cause toxicity by a
number of mechanisms though questions remain as to
whether NFT are the main culprit of tau-induced toxicity.Molecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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Non-filamentous tau intermediates and neurotoxicity
The development of NFT is initiated by the formation of
pre-tangles of oligomeric tau that assemble into insoluble
filaments before aggregating to form NFT. Prior to, during
or after this process, tau undergoes numerous, and poten-
tially harmful, modifications. Therefore, though NFT may
themselves be neurotoxic, the presence of some of these
modifications may be indicative of tau-mediated damage
that arose before their deposition. Indeed, tau-mediated
neuronal death, in the absence of tau filaments, is
observed in Drosophila and some transgenic mouse mod-
els overexpressing htau [65-67]. Mice overexpressing htau
with the P301L mutation (rTg4510 mice) do develop age-
related NFT, neuronal loss and memory impairments. Yet,
the subsequent suppression of the mutant tau stabilizes
neuronal loss and improves memory function even
though NFT continue to accumulate [47]. In rTg4510, a
regional dissociation between neuronal loss and the accu-
mulation of NFT is observed; there is a loss of neurons in
the dentate gyrus before NFT lesions appear and, con-
versely, NFT appear without major cell loss in the striatum
[68]. Likewise, many of the neurons that accumulate NFT
in aged transgenic mice overexpressing normal htau seem
"healthy" in terms of nuclear morphology, while a
number of dying neurons do not appear to have a signifi-
cant load of tau filaments [69]. Furthermore, using mod-
els based on quantitative data on neuron loss and NFT
formation as a function of disease duration, it is estimated
that CA1 hippocampal neurons in AD can survive with
NFT for approximately 20 years [70]. Together, these stud-
ies suggest that tau-mediated neuronal death does not
require the formation of NFT. Rather, non-filamentous
tau, as well as abnormally modified tau intermediates,
may be neurotoxic. Indeed, tau can undergo numerous
post-translational modifications and some of these mod-
ifications, like phosphorylation and glycosylation, are
believed to occur early in the development of tau pathol-
ogy [71,72]. However, it is not yet known which tau inter-
mediates are critical for the development of the different
stages of neurodegeneration and by which mechanisms
these intermediates cause cellular injury.
Tau hyperphosphorylation
The phosphorylation of tau plays a physiological role in
regulating the affinity of tau for microtubules. Though less
well studied, phosphorylation also regulates the binding
of tau to signaling molecules and could thus influence
tau-mediated signaling [21]. Most of the phosphorylation
sites on tau are present in the proline-rich and the C-ter-
minal regions flanking the microtubule binding domains
(Fig 1); (for review, see [73]). The kinases that phosphor-
ylate tau can be divided into two major groups, according
to motif specificity: proline-directed protein kinases
(PDPK) and non-proline-directed protein kinases (non-
PDPK). The PDPK include cyclin-dependent kinase 5
(cdk5), mitogen-activated protein kinase, and several
stress-activated protein kinases. GSK3-β is often described
as a PDPK but the proline is not always required for phos-
phorylation by GSK3-β. Both cdk5 and GSK3-β co-purify
with microtubules [74,75] and phosphorylate tau within
a cellular environment [76,77]. The phosphorylation of
tau by these kinases inhibits the ability of tau to promote
microtubule assembly and facilitates the polymerization
of tau into PHF [78-81]. Among the non-PDPK are cyclic
AMP-dependent protein kinase (PKA), calcium- and cal-
modulin-dependent protein kinase II (CaMKII), and
microtubule affinity regulating kinase (MARK), the mam-
malian homologue of PAR-1. MARK targets KXGS motifs
within the microtubule binding repeat domains (serine
residues at 262, 293, 324 and 356) of tau [82]. Tau phos-
phorylation at KXGS motifs induces its dissociation from
microtubules and prevents its degradation [83]. Unbound
tau may then be hyperphosphorylated by other kinases. In
fact, the phosphorylation of tau by MARK/PAR-1 may be
a prerequisite for the action of downstream kinases,
including GSK-3β and Cdk5 [84]. There is also evidence
that tau can be phosphorylated on tyrosine residues
(Tyr18, Tyr29, Tyr197 and Tyr394) [85-89].
Tau hyperphosphorylation is an early event in the patho-
genesis of tauopathies, appearing before the development
of NFT [71]. Several missense mutations (G272V, P301L,
V337M and R406W) in FTDP-17 result in tau proteins
that are more favorable substrates to kinases in vitro [90].
In AD brains, the levels of total tau are approximately
eight-fold higher than in age-matched controls, and this
increase is due to higher levels of abnormally hyperphos-
phorylated tau, either polymerized into NFT of PHF or
straight filaments, or present as a non-fibrillized form in
the cytosol [50,91]. Elevated levels of hyperphosphor-
ylated tau are also detected in cerebral spinal fluid of AD
patients and may be predictive of neurodegeneration
[92,93]. The increase in tau protein is not likely to result
from increased transcription since several studies failed to
observe increased tau mRNA levels in AD brains com-
pared to controls [94-98], though one study did report a
relative downregulation of 3R-tau mRNA and an upregu-
lation of 4R-tau mRNA in areas heavily affected by NFT
[99]. Since these studies did not examine tau mRNA
expression at the cellular level, it remains possible that dif-
ferences in tau mRNA levels between AD and normal
cases occur in selective cell subpopulations. Interestingly,
while one study found no change in tau mRNA isoform
expression in AD, it did find that levels of mRNA for 4R-
tau isoforms were increased in the brainstem, but not the
fontal cortex or cerebellum, of patients with progressive
supranuclear palsy [98].
There is ample experimental evidence to support the view
that hyperphosphorylated tau plays a pathological role inMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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tauopathies. For example, the expression of pseudophos-
phorylated tau, which mimics disease-like tau hyperphos-
phorylation, causes apoptosis in neuronal cells, an effect
not observed when cells express wild-type tau [100]. The
co-transfection of tau with GSK-3β in a cell culture model
results in more cell death compared to the expression of
tau and mutant (inactive) GSK-3β, suggesting that tau
phosphorylation by GSK3-β is toxic [101]. In a similar
fashion, the activation of cdk5 by overexpressing p25
accelerates tau phosphorylation and aggregation in mice
overexpressing mutant (P301L) tau [102]. In fact, p25
overexpression and the ensuing cdk5 activation even con-
tribute to tau pathology in mice expression only endog-
enous tau. Some studies have shown that p25 transgenic
mice show increased tau phosphorylation compared to
wild-type controls and, although NFT are not present,
cytoskeletal components are disorganized, axonal swell-
ing is observed, and the affected axoplasm is filled with
abnormally clustered mitochondria and lysosomes, fea-
tures consistent with loss of a functional microtubule net-
work [103,104]. Cruz et al., (2003) also examined cdk5
activation on tau pathology and this group used bitrans-
genic mice that inducibly overexpress human p25 in the
forebrains of mice. In these mice, a time-dependent
increase in neuronal loss and astrogliosis is observed in
the cerebral cortex between 5 and 12 weeks of cdk5 induc-
tion. Tau phosphorylation is increased in p25 transgenic
mice compared to controls but there is no marked change
in total tau protein levels. By 27 weeks of cdk5 induction,
NFT pathology is visible in the cerebral cortex and hippoc-
ampus [105]. Together, these results provide compelling
evidence that aberrant tau hyperphosphorylation can lead
to neurodegeneration, even in the absence of tau muta-
tions or forced tau overexpression. Of interest, cdk5 activ-
ity is elevated in the prefrontal cortex of AD brains, where
NFT are found, but not in the cerebellar cortex suggesting
a relationship between deregulated cdk5 activity and tau
pathology in humans [106,107].
Not only may increased kinase activity participate in tau
hyperphosphorylation, but so may decreased tau dephos-
phorylation. Tau is dephosphorylated by protein phos-
phatase 2A (PP2A) and, to a lesser extend, by PP1, PP2B
and PP5 [19,108-110]. In the human brain, PP2A, PP1,
PP5 and PP2B account for approximately 71, 11, 10 and
7%, respectively, of the total tau phosphatase activity
[110]. The mRNA and protein expression of some phos-
phatases, as well as their activities, are decreased in
affected areas of AD brain [96,110-114]. For example, in
the AD hippocampus, PP2A and PP1 mRNA levels are
decreased [111] and the protein expression level of PP2A
subunits is significantly and selectively decreased in AD-
affected brain regions and in tangle-bearing neurons
[114]. Indeed, the progressive loss of PP2A subunit
expression closely parallels the formation of tau lesions in
discrete neurons [114]. Compared to controls, phos-
phatase activity towards hyperphosphorylated tau is
lower in gray matter extracts from AD brains [112] and
PP2A activity is decreased in homogenates from the fron-
tal and temporal cortices [114]. Of interest, one study
found that the activities of PP2A and PP5 are decreased in
the AD brain but PP2B activity is increased [110]. None-
theless, the total phosphatase activity in this study was sig-
nificantly lower [110] and another study has shown PP2B
activity to be decreased in the AD brain [113]. Together,
these findings suggest that the downregulation of phos-
phatase activity, especially that of PP2A, can contribute to
increasing levels of hyperphosphorylated tau. Consistent
with this notion, PP2A inhibition by okadaic acid induces
tau hyperphosphorylation and accumulation in rat brain
slices [109] and the inhibition of PP2A and PP1 activity by
calyculin A injections into the rat hippocampus leads to
tau hyperphosphorylation and defects in spatial memory
retention [115]. Moreover, transgenic mice with reduced
neuronal PP2A activity exhibit increased tau hyperphos-
phorylation and the accumulation of tau aggregates in the
soma and dendrites of cortical pyramidal cells and cere-
bellar Purkinje cells [116].
Tau phosphorylation is also regulated by Pin1 (protein
interacting with NIMA 1), a member of the peptidyl-pro-
lyl cis-trans isomerase group of proteins involved in the
assembly, folding and transport of cellular proteins. The
interaction between tau and Pin1 depends on the phos-
phorylation state of tau; Pin1 binds tau when phosphor-
ylated at Thr231 [117] and facilitates its
dephosphorylation by PP2A [118-120]. In AD neurons,
Pin1 binds hyperphosphorylated tau in PHF, potentially
depleting soluble Pin1 levels [117,121]. Pin1 is signifi-
cantly down-regulated and oxidized in the AD hippocam-
pus [122]. Additionally, pyramidal neurons from AD
brains that have lower Pin1 levels are more prone to con-
tain tangles, whereas neurons with higher levels of Pin1
are generally tangle-free [123]. Deregulation of Pin1
expression and activity could induce an imbalance in the
phosphorylation-dephosphorylation of tau and nega-
tively impact tau regulation and function. Indeed, Pin1
restores the ability of phosphorylated tau to bind micro-
tubules and promote microtubule assembly in vitro [117].
It has been proposed that Pin1 functions as a co-chaper-
one and, together with HSP90 and other members of the
HSP90 complex, is involved in the refolding and dephos-
phorylation of aberrantly phosphorylated tau [83]. If Pin1
levels are knocked-down in Hela cells by siRNA prior to
transfecting cells with wild-type tau, tau levels are
decreased compared to Pin1-expressing cells [83]. This
suggests that when Pin1 levels are decreased, attempts to
refold/dephosphorylate tau are subverted and tau degra-
dation is favored. However, Pin1 knock-down increases
the stability of wild-type tau, as well as that of V337M and
R406W mutant tau in SH-SY5Y cells [124]. Differences in
the results among these two studies may reflect differencesMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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in the culture models used and experimental design. It is
also possible that, in the absence of Pin1 and its associ-
ated dephosphorylation and refolding activities, the deg-
radation machinery may become overburdened, leading
to tau accumulation. It should also be noted that, while
knocking-down Pin1 increases the stability of wild-type
tau and various mutant forms of tau in SH-SY5Y cells, it
decreases the stability of P301L- and P301S-tau [124]
indicating that the effect of Pin1 on tau is mutation-
dependent. Of interest, Pin1-/- mice develop age-depend-
ent neuropathy, characterized pathologically by tau
hyperphosphorylation, tau filament formation and neu-
ronal degeneration in the brain and spinal cord [123],
thus providing another model in which the hyperphos-
phorylation of endogenous tau correlates with neuronal
death. Conversely, Pin1 overexpression reduces tau levels
and suppresses the tauopathy phenotype in transgenic
mice expressing wild-type tau [124]. However, in keeping
with the opposing effects of Pin1 on wild-type tau and
P301L-tau in SH-SY5Y cells, Pin1 overexpression exacer-
bates the tauopathy phenotype in P301L tau transgenic
mice. Moreover, when Pin1-/- mice are crossed with trans-
genic mice overexpressing mutant (P301L) tau, P301L
mutant tau levels are decreased and the robust tauopathy
phenotype is abolished [124].
Though many questions remain regarding the cause of
aberrant tau phosphorylation in tauopathies, tau hyper-
phosphorylation is believed to play an important role in
tau-mediated toxicity. Soluble hyperphosphorylated tau
isolated from AD brains has lower microtubule-promot-
ing activity in vitro [125] and sequesters normal tau, MAP1
(A/B) and MAP2, causing the inhibition of microtubule
assembly and even the disassembly of microtubules
[126,127]. These findings suggest that hyperphosphor-
ylated tau can cause the breakdown of microtubules by
interacting with microtubule associated proteins. Conse-
quently, one could thus speculate that hyperphosphor-
ylated tau is involved in the depletion and abnormal
orientation of microtubules that is observed in the frontal
cortex layers II and III in AD brains [58]. An expected con-
sequence of disarrayed or depleted microtubules is the
impairment of microtubule-based transport, also an early
event observed in AD [128,129]. As previously men-
tioned, loss of tau function alone may be insufficient to
disrupt microtubule networks [61]. However, the com-
bined loss of tau and other microtubule-associated pro-
teins could have more detrimental consequences on
microtubule regulation. Consistent with this is the obser-
vation that mating tau-/- and MAP1B-/- mice leads to a
lethal postnatal phenotype [62].
Unlike the soluble form of hyperphosphorylated tau, the
filamentous form of tau does not bind MAPs and does not
disrupt microtubules in vitro [56]. Not only does this
imply that tau filaments would have less of an impact on
the microtubule network, the formation of filaments may,
in fact, be a mechanisms adopted by neurons to sequester
the toxic forms of hyperphosphorylated tau. However, if
NFT are detrimental to cells, and if tau hyperphosphoryla-
tion facilitates aggregation and filament formation, this
could be one more mechanism by which tau hyperphos-
phorylation contributes to neuronal death. When hyper-
phosphorylated tau isolated from the AD brain is
dephosphorylated by PP2A, the ability of tau to polymer-
ize into PHF is inhibited. Conversely, the sequential
rephosphorylation of tau by PKA, CaMKII, and GSK3-β or
cdk5, as well as by GSK3-β and cdk5, promotes the assem-
bly of tau into tangles of PHF similar to those observed in
the AD brain [130]. Yet, the in vitro phosphorylation of
recombinant tau promotes the formation of tau filaments
in some studies [130,131] but not all [132], putting into
question the role of tau phosphorylation in enhanced fil-
ament formation.
Another mechanism by which tau hyperphosphorylation
may contribute to neuronal toxicity is through its interac-
tion with actin. In Drosophila and mice, tau leads to the
accumulation of filamentous actin into structures resem-
bling the Hirano bodies observed in the brains of patients
with AD or other tauopathies, like Pick's disease [11].
Hirano bodies are intraneuronal inclusions that contain,
among other proteins, actin and tau [133,134], and may
play a causative role in AD [135,136]. The formation of
Hirano body-like structures in neurons disrupts microtu-
bules in neurites and could thus impair axonal transport
and lead to synapse loss [135]. Fulga et al., (2007) have
shown that phosphorylated tau can induce changes in the
actin cytoskeleton and lead to toxicity. The retinal expres-
sion of pseudophosphorylated tau in Drosophila induces a
striking accumulation of actin in the lamina and produces
substantial toxicity. Conversely, the expression of phos-
phorylation-incompetent tau does not lead to actin accu-
mulation and only causes mild toxicity [11]. These results
suggest that phosphorylated tau can cause neuronal death
by inducing changes in the actin cytoskeleton.
Overall, though tau hyperphosphorylation is implicated
in tau pathology, it is still not fully understood which of
the tau phosphorylation sites are critical for the develop-
ment of tauopathies, nor is it decidedly known how
hyperphosphorylated tau causes neuronal death. A better
understanding of the physiological roles of tau phospho-
rylation, as it regulates the binding of tau to microtubules
and affects other less well characterized functions of tau,
will likely shed light on the mechanisms by which tau
hyperphosphorylation contributes to cell death.
Other tau modifications
Intimately linked to tau phosphorylation is tau glycosyla-
tion. Glycosylation is characterized by the covalent attach-
ment of oligosaccharides to protein side chains.Molecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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Glycosidic bonds are classified as either N-linked or O-
linked. In N-linked glycosylation, the sugar is linked to
the amide group of asparagine residues of proteins, while
in O-linked glycosylation, sugars are attached to a
hydroxyl group of serine or threonine residues. Hyper-
phosphorylated tau and PHF-tau purified from AD brains
are glycosylated, mainly through N-linkage [137,138].
Additionally, non-hyperphosphorylated tau isolated from
AD brains is also glycosylated, whereas no glycan is
detected in tau purified from normal control brains [137],
suggesting that aberrant glycosylation precedes abnormal
tau hyperphosphorylation. Indeed, glycosylation facili-
tates the site-specific phosphorylation of tau catalyzed by
PKA, cdk5 and GSK-3β [137,139]. Conversely, glycosyla-
tion appears to inhibit the dephosphorylation of tau by
PP2A and PP5 [140]. Tau glycosylation may also coordi-
nate with hyperphosphorylation to stabilize the filamen-
tous structure of PHF given that deglycosylation of PHF
untwists PHF into straight filaments [137]. Together,
these findings suggest that aberrant N-linked glycosyla-
tion is an early tau modification that enhances tau hyper-
phosphorylation, which may drive NFT formation, and
also help maintain and stabilize NFT structures.
In addition to N-linked glycosylation, human brain tau
can be modified by O-linked monosaccharide β-N-
acetylglucosamine (O-GlcNAc) [141]. O-GlcNAcylation
regulates tau phosphorylation in a site-specific manner in
both cultured cells overexpressing htau and in rodent
brains; at most of the phosphorylation sites examined, O-
GlcNAcylation reduces tau phosphorylation [141]. Con-
sistent with this finding, in neuroblastoma cells trans-
fected with htau, O-GlcNAc mainly modifies the less-
phosphorylated tau species, while highly phosphorylated
tau is devoid of O-GlcNAc residues [142]. In starved mice,
a model used to mimic the reduction in glucose uptake
and metabolism observed in the AD brain, O-GlcNAcyla-
tion is decreased and tau hyperphosphorylation is
increased in the brains of the mice [141]. In the AD brain,
the level of O-GlcNAcylation is lower than that in control
brains, indicating that O-GlcNAcylation is compromised
[141]. Based on these findings, it was proposed that
impaired glucose metabolism in AD may contribute to
disease pathogenesis by reducing tau O-GlcNAcylation
and, consequently, increasing tau phosphorylation [143].
Yuzwa et al., (2008) have shown that Thiamet-G, an
inhibitor of O-GlcNAcase that enhances O-GlcNAcyla-
tion, markedly reduces tau phosphorylation in PC12 cells
at pathologically relevant sites, like Thr231 and Ser396.
Moreover, Thiamet-G also efficiently reduces phosphor-
ylation of tau at Thr231, Ser396 and Ser422 in both the rat
cortex and hippocampus [144]. Together, these findings
underscore the dynamic relationship between the O-Glc-
NAcylation and phosphorylation of tau.
Besides phosphorylation and glycosylation, tau under-
goes other changes that could enhance tau self-assembly
and filament formation and may confer toxic gains or loss
of function. For instance, the proteolytic cleavage of tau
coincides with the pathogenesis of AD. Granular aggrega-
tions containing tau truncated at Glu391 are detected
within the somatodendritic compartment of AD brains
but not in age-matched non-demented controls [145],
Glu391-truncated tau is present in PHF isolated from AD
tissue [146-148] and tau-truncated at Asp421 associates
with neurofibrillary pathology in AD brains [149-151].
Tau cleaved at Glu391 and/or Asp421 is also observed in
Pick's disease, progressive supranuclear palsy and cortico-
basal degeneration [152-154].
The truncation of tau accelerates its assembly into fibrils
in vitro [149,155,156], promotes microtubule assembly in
vitro  more than full-length tau [157], and increases its
association with microtubules [158]. The effect of tau
phosphorylation at Ser396/Ser404 on microtubule bind-
ing differs between full-length tau and tau truncated at
Asp421, indicating that specific tau forms (e.g. intact ver-
sus cleaved tau) respond differently to site-specific phos-
phorylation [158]. Notably, transgenic rats that
overexpress truncated tau species (aa 151–391) in the
brain and spinal cord develop neurofibrillary pathology
[157], and cultured cortical neurons derived from these
rats have fewer mitochondria in neuronal processes, dis-
play higher levels of reactive oxygen species and are more
susceptible to oxidative stress compared to cultures from
non-transgenic rats [159]. Consistent with these findings,
the expression of tau fragments cause cell death or render
cells more sensitive to insults in various culture models
[160-163].
Taken together, the above findings suggest that tau cleav-
age is neurotoxic. However, there is some debate as to
whether tau cleavage occurs before or after the aggregation
of tau into NFT. On the one hand, Guillozet-Bongaarts et
al., (2004) have shown by immunohistochemical studies
that tau truncation at Asp421 occurs only after the Alz50
conformation change in tau, the presence of which is
indicative of the appearance of filamentous tau [164]. On
the other hand, the deletion of CHIP, a tau ubiquitin
ligase, leads to the accumulation of non-aggregated,
hyperphosphorylated and caspase-cleaved tau in mice,
suggesting that tau hyperphosphorylation and caspase-3
cleavage both occur prior to aggregate formation [165].
Indeed, Rissman et al. (2004), show that in both trans-
genic mice and in AD brain, caspase-cleaved tau at Asp421
associates with early and late markers of NFT and corre-
lates with cognitive decline [150].Molecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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In addition to the incorporation of truncated tau into
NFT, the PHF and NFT in AD brains are glycated [166] as
well as ubiquitinated [167,168], but these modifications
are believed to be later events in disease progression.
Nitrated tau is also detected in cytoplasmic inclusions in
AD, corticobasal degeneration, Pick's disease, progressive
supranuclear palsy and FTPD-17 [169]. Tau-nY29, an anti-
body specific for tau when nitrated at Tyr29, detects solu-
ble tau and PHF-tau from severely affected AD brains but
fails to recognize tau from normal aged brains, suggesting
that tau nitration is disease-specific [170]. The exact mech-
anisms by which nitrated tau contributes to pathology,
however, remain poorly understood. Nitration can greatly
affect protein folding and function [171,172]. Peroxyni-
trite (ONOO-), which is capable of both protein nitration
and oxidation [173], leads to tau oligomerization in vitro
and in neuroblastoma cells [174,175]. Yet, it is believed
that this effect results from the oxidative role of peroxyni-
trite and the formation of dityrosine bonds in tau [175].
The overall effect of tau nitration by peroxynitrite in vitro
is to delay the polymerization of tau into filaments
[175,176]. The toxicity of tau nitration may instead result
from the inhibitory effect of nitration on the ability of tau
to promote tubulin assembly which could compromise
microtubule function [177].
Tau mutations
Even though no mutations in tau have been identified in
AD or sporadic cases of frontotemporal dementia, under-
standing how mutations in tau confer toxicity in FTDP-17
should provide insight on the role of tau in the develop-
ment of neurodegeneration. At least 34 mutations in the
human MAPT gene, falling into two functional classes,
have been reported (Fig. 1) [178]. The first class of muta-
tions, which includes missense and deletion changes in
the coding region of MAPT, generates tau proteins with
altered function. These mutations can reduce the binding
affinity of tau for microtubules [38,39]. LeBoeuf et al.,
(2008) have shown that FTDP-17 tau mutations that map
to the repeat/inter-repeat region of tau compromise its
ability to regulated microtubule dynamics in vitro [179].
However, cells transiently expressing mutant (P301L or
R406W) or wild-type tau are indistinguishable in terms of
the co-localization of tau with microtubules and the gen-
eration of microtubule bundles [180], implying that these
tau mutations do not have an immediate impact on the
integrity of the microtubule system. In addition to
impaired microtubule binding, first class mutations
enhance the ability of tau to aggregate and form filaments
in vitro [41,42,44]. Insoluble aggregates in patients with
the P301L mutation consist largely of mutant 4R-tau, with
only small amounts of normal 4R- and 3R-tau [181]. The
selective trapping of P301L tau in the insoluble deposits is
presumably caused by the increased aggregation potential
conferred by the mutation. It is tempting to speculate that
the combined effects of altered microtubule regulation
and accelerated NFT formation caused by mutations in
tau contribute to tau-mediated toxicity or, at the very least,
render cells more vulnerable to age-related stressors.
The second class of mutations affects the alternative splic-
ing of MAPT transcripts, mainly influencing exon 10 splic-
ing and leading to a change in the ratio of tau isoforms
with three of four microtubule binding repeats. In the
normal adult brain, the ratio of 4R- to 3R-tau is approxi-
mately 1. Many of the second class mutations increase this
ratio [29], suggesting that 4R-tau is the more toxic iso-
form. However, while only 4R-tau aggregates into twisted
and straight filaments in corticobasal degeneration and
progressive supranuclear palsy, NFT in AD brains contain
both 3R- and 4R-tau, and 3R-tau inclusions are primarily
observed in Pick's disease [182-184]. Therefore, neurode-
generation may not result from one isoform being more
toxic than another, but rather from an imbalance in the
proper ratio of 3R- to 4R-tau. One hypothesis proposes
that since splicing mutations cause an excess of a specific
tau isoform and, since 3R- and 4R-tau bind microtubules
at different sites [185], a shortage of available binding
sites would occur for the overexpressed tau isoform [186].
This could lead to an excess of free tau available for fila-
ment assembly. It is also highly probable that abnormal
changes in isoform expression would adversely affect tau
function. Given that various tau isoforms are differentially
expressed during development, differentially distributed
in neuronal subpopulations and even present in distinct
localizations within neurons [187], it is likely that they
have specific functions. For example, different tau iso-
forms have dramatically different effects on the rate and
number of motors driving the cargo along microtubules
[188]. As our understanding of the functions carried out
by distinct tau isoforms grows, so will our understanding
of how alterations in their expression levels contribute to
neuronal dysfunction.
Mechanisms of tau toxicity
Impaired axonal transport and synaptic damage
It is clear that tau undergoes several abnormal modifica-
tions during the evolution of tauopathies. Different tau
intermediates are likely to play various roles in the onset
and progression of disease and several modifications of
tau may have converging mechanisms of toxicity. While
many questions remain, a better understanding of the
early events in tau-mediated toxicity is especially impor-
tant as it may lead to the development of therapeutic strat-
egies that prevent the pathological events that initiate
neuronal dysfunction. Synaptic damage is an early event
in AD [189] and synapse loss correlates with cognitive def-
icits even more strongly than the number of NFT
[190,191]. In addition to AD, synapse loss is reported in
other tauopathies, like progressive supranuclear palsyMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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[192] and frontal lobe degeneration of non-Alzheimer
type [193,194].
Animal models of tauopathy provide evidence that defects
in tau can cause synaptic damage. Yoshiyama et al.
(2007), show that hippocampal synaptic loss is observed
in transgenic mice overexpressing P301S htau (PS19
mice) before NFT formation [195]. These mice develop
early synaptic pathology; a prominent decrease in levels of
the pre-synaptic proteins, synaptophysin and β-synuclein,
is detected in the CA3 region of hippocampus by 3
months of age. To examine the functional consequence of
synaptic pathology, in vivo electrophysiology was con-
ducted using 6 month old PS19 mice, an age that precedes
marked NFT formation and neuronal loss. At this age, syn-
aptic conduction, presynaptic function and long-term
potentiation, thought to underlie learning and memory,
are impaired in PS19 mice compared to non-transgenic
controls. In agreement with this study, Eckermann et al.,
(2007) reported that a reduction in the number of spine
synapses in tau transgenic mice occurs in the absence of
NFT formation. For their study, two transgenic mouse
lines were created. One line expresses full-length htau
with the ΔK280 mutation that strongly promotes tau
aggregation. The second line contains the same ΔK280
mutation and two additional proline mutations (ΔK280/
PP) to disrupt aggregation. The hyperphosphorylation of
tau and the missorting of tau to the somatodendritic com-
partment are observed in both mutants but conforma-
tional changes in tau are observed only in the pro-
aggregation mice. Of particular interest, though the for-
mation of NFT is not observed in either line, synapse loss
is greater in the transgenic animals expressing the pro-
aggregation mutant of tau compared to animals express-
ing the anti-aggregation mutant. This suggests that the
ability of tau to form oligomers is likely to hasten synaptic
decline while supporting the notion that overt filament
formation is not necessary for synaptic loss [196]. In
agreement with this, the accumulation of early-stage
aggregated tau species, which antecedes the formation of
NFT, is associated with the development of functional def-
icits during the pathogenic progression in rTg4510 mice
[197]. As observed in mice, tau-induced synaptic dysfunc-
tion is seen before any evidence of neuronal death or NFT
formation in Drosophila [198]. The overexpression of htau
in larval motor neurons causes a disruption of axonal
transport and reduces the number of detectable mito-
chondria in the presynaptic terminals of neuromuscular
junctions. Tau-expressing neuromuscular junctions are
functionally abnormal, exhibiting disrupted vesicle
cycling and impaired synaptic transmission.
Various mechanisms by which non-fibrillar tau could dis-
rupt axonal transport and cause synaptic damage have
been proposed. One possibility is that tau hyperphospho-
rylation leads to microtubule disassembly and loss of the
tracks needed for transport. As previously mentioned, sol-
uble hyperphosphorylated tau isolated from AD brains
has decreased microtubule-promoting activity in vitro
[125,199] and sequesters normal tau, MAP1 (A/B) and
MAP2, causing the inhibition of microtubule assembly
and even the disassembly of microtubules [126,127]. In
so doing, the hyperphosphorylation of tau may destabi-
lize microtubules, thus impairing the microtubule tracks
needed for the transport of molecular motors and their
cargo. A second possibility is that transport inhibition
results from too much tau binding microtubules and
essentially blocking the movement of motor proteins
[200,201]. The transfection of htau in mature hippocam-
pal neurons results in the overexpression and improper
distribution of tau so that it invades dendrites in addition
to axons. The high levels of tau cause transport inhibition
of mitochondria. This may be because tau either displaces
motor proteins from microtubules or prevents their asso-
ciation to microtubules by covering the microtubule sur-
face. Additionally, tau overexpression causes
microtubules to bundle and this further impedes mito-
chondrial movement, leading to mitochondrial degenera-
tion, loss of ATP and synaptic degeneration [201]. In this
model, tau-mediated synaptic loss is delayed by overex-
pressing the kinase MARK2/PAR-1, which increases tau
phosphorylation at the KXGS motif. Since phosphoryla-
tion of tau at this site detaches tau from microtubules, it is
thought that MARK2/PAR-1 activation postpones synap-
tic degeneration by removing tau from the microtubule
tracks and reversing the transport block. It should be kept
in mind that, although modifications in tau may lead to
its accumulation in tauopathies, the overexpression of tau
in this model may increase tau levels beyond what is
observed in disease. Finally, evidence is now emerging
that the ability of tau to impair axonal transport does not
necessarily involve microtubule dysfunction. As it hap-
pens, tau itself binds kinesins [202,203] and is trans-
ported along axons as kinesin cargo [204]. This raises the
possibility that high levels of unbound tau may compete
with potential kinesin cargo and thus prevent their trans-
location to the synapse. Indeed, co-immunoprecipitation
experiments show that when full-length tau is overex-
pressed in differentiated NB2a/d1 cells, the binding of
kinesin to vimentin and neurofilament medium (NF-M)
is decreased, presumably because these proteins are dis-
placed from kinesin by tau [202]. Furthermore, when tau
is co-transfected in cells overexpressing NF-M, the antero-
grade transport of NF-M is selectively decreased while the
percentage of non-moving NF-M, as well as NF-M exhibit-
ing retrograde transport, increases [202]. Since retrograde
transport is not impaired, it is unlikely that the inhibition
of anterograde axonal transport resulting from tau overex-
pression is caused by altered microtubule dynamics. In
contrast to these findings, the perfusion of full-lengthMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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htau, at a physiological concentration, does not reduce
anterograde fast axonal transport in isolated squid axo-
plasm [64]. However, when axoplasm is perfused with tau
isoforms lacking the C-terminus, anterograde (but not ret-
rograde) transport is inhibited [64]. Together, these
results suggest that tau modifications or its accumulation
beyond normal physiological levels, are required for tau
to affect axonal transport. Notably, Cuchillo-Ibanez et al.,
(2008) report that the phosphorylation state of tau regu-
lates its ability to bind kinesin-1; tau phosphorylated by
GSK-3 associates with the light chain of kinesin-1 more
than dephosphorylated tau [203]. Of interest, in cortical
neurons transfected with full-length tau, the inhibition of
GSK-3 reduces tau phosphorylation and decreases the rate
of fast axonal transport of tau. In contrast, tau pseudo-
phosphorylation mutants for GSK-3 sites are transported
significantly faster compared to wild-type tau [203]. Based
on the above findings, it is tempting to speculate that
hyperphosphorylated tau would be better than normal
tau at scavenging kinesin and displacing other kinesin
cargo, thus preventing their anterograde axonal transport.
It ought to be mentioned that, although filament deposi-
tion may not be necessary for tau-mediated transport
inhibition and synapse loss, it is likely to enhance synap-
tic damage. In lamprey central neurons that overexpress
the shortest isoform of htau, tau filament formation
appears to precede the beading of distal dendrites and the
progressive loss of dendritic microtubules and synapses
[205]. In this model, filament assembly occurs surpris-
ingly rapidly; neurons expressing htau for 5–10 days con-
tain densely packed htau filaments throughout their
somata and dendrites. In this system, synaptic loss may be
caused by large NFT that physically obstruct the move-
ment of mitochondria along microtubules or may be due
to the ability of NFT to inhibit fast axonal transport by
triggering the release of cargo from kinesin [64].
Aberrant tau-mediated intracellular signaling
Though the role of tau in regulating microtubule dynam-
ics is well established, much less is known regarding the
role of tau in other cellular functions. Given the ability of
tau to interact with the plasma membrane and to bind a
variety of proteins, tau is proposed to participate in cell
signaling. Potential signaling proteins that bind tau
include PP1 [18], PP2A [19], the scaffolding protein 14-3-
3 [20] and phospholipase Cγ (PLCγ1) [16,21]. Addition-
ally, tyrosine kinases (Fyn, cSrc, Lck and Fgr), the p85a
regulatory subunit of phosphatidylionositol 3-kinase and
PLCγ1 have been shown to bind tau through their SH3
domains [17,21]. SH3 domains recognize the PXXP motif
in proteins, seven of which are present in htau close to
known tau phosphorylation sites. The binding of tau to
signaling molecules implies that tau is either a substrate to
the binding enzyme or that tau regulates the activity of the
protein to which it is bound. With some binding partners,
both situations may be true. For example, tau is not only
phosphorylated by Fyn [85,206] it also modulates Fyn
activity [207]. Tau increases PLCγ activity in vitro [208],
and also increases Fyn and Src kinase activity both in in
vitro assays and within COS7 cells [207]. Additionally, tau
primes Src for activation in 3T3 cells stimulated with
platelet-derived growth factor, as reflected by sustained
actin stress fiber breakdown [207]. These results suggest
that tau can impact actin remodeling by upregulating Src
tyrosine kinase activity.
It is worth noting that the phosphorylation of tau alters its
ability to bind SH3 domains [21,206]. Tau isolated from
normal human brain is able to bind SH3 domains but
PHF-tau isolated from AD brains cannot [21]. Similarly,
the interaction between tau and the plasma membrane is
modulated by the phosphorylation state of tau
[14,15,209]. In human neuroblastoma cells [209] and in
PC12 cells [15], plasma membrane-bound tau is less
phosphorylated than cytoplasmic or total tau. Further-
more, when PC12 cells are transfected with wild-type
htau, a substantial amount of tau is isolated in the plasma
membrane fraction. In contrast, when cells are transfected
with tau pseudophosphorylation mutants to mimic PHF-
tau, no tau is present in the plasma membrane fraction
[15]. Thus, abnormal alterations in the phosphorylation
state of tau may aberrantly affect its association with the
plasma membrane and with various signaling proteins. It
is not yet known if other abnormal tau modification
would do so as well.
Tau-enhanced vulnerability
Several forms of neurotoxicity are hypothesized to be
involved in the etiology of AD. Among them are inflam-
mation, oxidative stress, mitochondrial dysfunction, cal-
cium dysregulation and excitotoxicity. Though none of
these are specific to AD, as they occur in a variety of neu-
rodegenerative diseases and/or with ageing, abnormalities
in tau may accelerate their development or render neu-
rons more vulnerable to these insults. For instance, tau-
mediated disruption of intracellular transport, and espe-
cially defects in mitochondria trafficking and the ensuing
decrease in ATP levels, may not only impair normal neu-
rotransmission, but may also render neurons more sus-
ceptible to age-related stressors. For example,
mitochondrial dysfunction increases the susceptibility of
neurons to excitotoxicity, the pathological process by
which excessive activation of glutamate receptors leads to
neurodegeneration [210,211]. Also, mitochondrial dys-
function can provoke the release of presynaptic glutamate
and impair the clearance of glutamate from the synapse,
thus leading to high levels of extracellular glutamate and
sustained glutamate receptor activation [212-214]. In fact,
cell death from tau overexpression in cultured neurons isMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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dependent on the activation of NMDA receptors, a sub-
type of glutamate receptor [215]. While not yet studied,
NMDA receptor activation by tau overexpression may be
due to increased glutamate levels caused by altered mito-
chondria trafficking or by a decrease in the expression of
glutamate transporters. Mice overexpressing tau in astro-
cytes show decreased expression and function of the glial
glutamate transporter, GLT-1 [216]. In addition to poten-
tially provoking excitoxic insults, Roberson et al., (2007)
propose a role for tau in modulating sensitivity to such
insults. The intraperitoneal injection of kainate, a gluta-
mate receptor agonist, dose-dependently induces seizures
in tau+/+ mice. In contrast, tau+/- and tau-/- mice are
resistant to kainate-induced seizures [217]. In a similar
fashion, compared to tau+/+ mice, tau+/- and tau-/- mice
are protected against the behavioral deficits caused by
overexpressing the human amyloid precursor protein
[217]. Tau reduction also provides protection against β-
amyloid toxicity in primary neurons [218,219]. For exam-
ple, cultured hippocampal neurons obtained from wild-
type animals degenerate in the presence of β-amyloid. In
contrast, cultures prepared from tau-/- animals show no
signs of degeneration [218]. Together, these studies pro-
vide evidence that the presence of tau increases the suscep-
tibility of neurons to β-amyloid and excitotoxic insults
and suggest that tau is a downstream mediator of β-amy-
loid-induced toxicity (for review, see [220]). Indeed, β-
amyloid influences the formation of NFT in tau transgenic
mice [221-224]. For example, the clearance of β-amyloid
by immunotherapy results in the removal of early-stage
tau pathology in triple transgenic mice (3xTg-Ad) that
normally develop β-amyloid plaques and NFT [224].
Conversely, when Lewis et al., (2001) crossed JNPL3
transgenic mice expressing P301L htau with Tg2576 trans-
genic mice expressing mutant APP, they found that the
double mutants exhibited enhanced NFT pathology in the
limbic system and olfactory cortex compared to JNPL3
mice [221]. Likewise, NFT tangle formation was aggra-
vated when APP mutant mice (APP23 mice) were crossed
with P301L tau transgenic mice, or when brain extracts
from aged APP23 mice with β-amyloid deposits were
intracerebrally infused in young P301L tau mice [223].
Gotz et al., (2001) reported that the injection of β-amy-
loid Aβ42 fibrils into the brains of P301L mutant tau trans-
genic mice markedly increased tau phosphorylation at
S212/T214 and S422, as well as the number of NFT, along
with neuropil threads and degenerating neurites in the
amygdala of P301L, but not wild-type, mice [222]. Simi-
larly, treating primary neuronal cultures [225-229] or
neuronal-like cells lines [230,231] with fibrillar β-amy-
loid induces tau phosphorylation and toxicity. In primary
hippocampal or cortical neurons, tau phosphorylation
induced by treating cells with fibrillar β-amyloid is an
early event followed by the somatodendritic accumula-
tion of hyperphosphorylated tau in a soluble form that is
not associated with microtubules and is incapable of
binding microtubules in vitro [225]. Of interest, treat-
ments that offer protection against β-amyloid-induced
toxicity, like lithium [228] or the glutamate receptor
antagonist, memantine [229], reduce tau phosphoryla-
tion. Together, these results suggest that β-amyloid trig-
gers tau hyperphosphorylation, NFT formation and
neurodegeneration.
Concluding remarks
Because of the complexity of tau biology, it is expected
that tau dysfunction contributes to toxicity via multiple
mechanisms and at different stages of disease. The early
axonal transport defects and synaptic damage could result
from tau hyperphosphorylation and cytosolic accumula-
tion whereas NFT, which may initially be formed as a pro-
tective mechanism to sequester toxic tau moieties, could
eventually contribute to neuronal death. Unfortunately,
despite the growing body of evidence in strong support for
the involvement of pathologically modified tau and tau
aggregates in neurodegeneration, the exact neurotoxic tau
species have not been definitively identified. Both toxic
gains of function and the loss of normal tau functions are
believed to play a role in inducing neuronal death but the
mechanisms by which this occurs remain elusive. Deci-
phering the causes and effects of tau-mediated toxicity are
complicated by the various tau isoforms, the numerous
abnormal tau modifications, as well as the likelihood that
tau intermediates contribute to the progression of neuro-
nal death at different phases of a lethal cascade of events.
This may well explain why several lines of investigation
have suggested diverse, and sometimes conflicting, mech-
anisms of tau toxicity. Some of the inconsistencies may
reflect differences among tau isoforms, mutations and
expression levels in the experimental models employed to
examine tau-mediated neurodegeneration. Additionally,
while these models have proven critical in our current
understanding of tauopathies, it should be kept in mind
that, in trying to recapitulate the formation of NFT within
neurons by artificially overexpressing tau, certain subtle
(but no less significant) changes in tau that contribute to
the initiation and evolution of disease may be over-
looked. Also complicating matters is the lack of knowl-
edge regarding the functions carried out by tau beyond its
well-established involvement in regulating microtubule
assembly and stability. Tau associates with the plasma
membrane and interacts with a number of proteins
involved in cell signaling. Until these additional tau func-
tions are better understood, the harmful consequences of
aberrant tau modifications, and how they adversely influ-
ence these functions, cannot to be fully appreciated. Thus,
continuing efforts should be made to further identify and
characterize tau functions and how they are negatively
affected by the accumulation of cytosolic tau, the altered
cellular distribution of tau, abnormal tau modificationsMolecular Neurodegeneration 2009, 4:13 http://www.molecularneurodegeneration.com/content/4/1/13
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and changes in the balance of tau isoforms. Such investi-
gations will not only offer insight on the mechanisms by
which tau causes neuronal dysfunction and death, but
may also help decipher the chronology of events involved
in tau-mediated toxicity. Indeed, a better understanding
of the initial events in tau-induced neurodegeneration is
likely to provide the basis for early therapeutic strategies.
Appendix 1: Key observations
- Tau plays a key role in the organization and integrity of
the neuronal cytoskeleton by regulating microtubule
dynamics. Hyperphosphorylated tau is the principal com-
ponent of neurofibrillary tangles in AD and related
tauopathies. The formation of NFT correlates with the
severity of cognitive impairment in AD, suggesting that
altered tau regulation plays an important role in the pro-
gression of tauopathies.
- Over 34 different tau mutations have been identified in
cases of FTDP-17, indicating that tau abnormalities are
sufficient to trigger neuronal death and dementia. Some
of the identified tau mutations disrupt tau-microtubule
interactions, accelerate filament formation or alter the
ratio of 4R- to 3R-tau isoforms.
- The aggregation of tau into NFT, as well as pathological
tau modifications (e.g. hyperphosphorylation), have been
linked to tau-mediated neuronal death in experimental
models of tauopathy. Cell culture and animal models in
which wild-type or mutant tau is overexpressed often reca-
pitulate key events observed in the progression of tauopa-
thies, such as tau hyperphosphorylation and
redistribution from axons to the somatodendritic com-
partment, synaptic damage, axonal degeneration, NFT
formation and cell death.
- Many therapeutic strategies for AD focus on the patho-
genicity of amyloid-β peptides. However, studies such as
the one showing that decreasing tau levels ameliorates the
amyloid-β-induced deficits in a mouse model of AD
[217], provide evidence to warrant tau-directed therapeu-
tic interventions.
Appendix 2: Critical next steps
- What are the toxic tau species and how do they influence
tau function? Evidence strongly supports the involvement
of pathologically modified tau and tau aggregates in neu-
rodegeneration but the exact neurotoxic species remain
unclear. Tau dysfunction likely contributes to cellular
demise via toxic gains of function as well as from the loss
of normal tau function. To appreciate the detrimental
consequences of a loss of tau function, more insight on all
functions of tau, and how they are regulated by different
tau isoforms or modifications, is critical.
- What is the sequence of events in tau-mediated death? Tau
dysfunction likely contributes to cellular demise via mul-
tiple mechanisms and at different stages of disease. A bet-
ter understanding of the causes of tau dysfunction (e.g.
altered kinase/phosphatase activity, diminished tau clear-
ance) may shed light on the initiating factors of tau
pathology and provide insight on the first toxic tau inter-
mediates. This information will be especially useful for
the design of therapeutic strategies aimed at targeting the
initial stages of tau-induced neurodegeneration.
- What tau-based therapeutic approaches will enhance the
clinical outcome of patients with tauopathies? Even though
many questions remain regarding tau's involvement in
neurodegeneration, our current understanding can guide
the development of tau-directed therapeutics. For exam-
ple, knowledge that the accumulation of hyperphosphor-
ylated tau plays a role in neurotoxicity, perhaps because
PHF tau can no longer stabilize microtubules, inspired
research on approaches aimed at inhibiting tau phospho-
rylation [232,233], eliminating pathological tau [83,234]
or restoring microtubule function through the use of
microtubule-stabilizing agents, like taxol [235]. These in
vivo studies provide evidence that targeting events in the
tau-cascade of neurotoxicity can be therapeutically benefi-
cial. Thus, future efforts must include the development
and testing of tau-based therapies.
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